Search results for "H. pylori"
showing 10 items of 14 documents
Ģimenes ārstu un speciālistu nozīmēto H.pylori eradikācijas shēmu salīdzinājums; to atbilstība vadlīnijām un efektivitāte
2016
Helicobacter pylori kolonizē kuņģa gļotādu vairāk nekā pusei pasaules iedzīvotāju. Pasaules Veselības organizācija ir pasludinājusi H. pylori par 1. grupas kancerogēno vielu. Latvijā H. pylori eradikācijas shēmas nozīmē atbilstoši Māstrihtas IV vadlīnijām. Pētījuma mērķis – salīdzīnāt ģimenes ārstu un speciālistu nozīmēto H. pylori eradikācijas shēmu efektivitāti un atbilstību vadlīnijām. Pētījumā piedalījās 550 pacienti, kuri bija ieradušies uz eradikācijas efektivitātes testa veikšanu. Ģimenes ārsti vadlīnijām atbilstošas eradikācijas shēmas bija nozīmējuši 85,8% gadījumu, bet gastroenterologi – 96,8% gadījumu. Ģimenes ārsti efektīvu H. pylori eradikācijas terapiju nozīmējuši 77,6% gadīju…
H.pylori eradikācijas shēmas un to efektivitāte Latvijas ģimenes ārstu un gastroenterologu praksēs
2017
H. pylori ir kuņģī mītošs patogēns, kurš visiem inficētajiem izsauc aktīvu hronisku gastrītu. V Māstrihtas vadlīnijas nosaka, ka vajadzētu piedāvāt veikt H. pylori eradikāciju visiem pacientiem, lai novērstu risku nākotnē attīstīties nopietnākām komplikācijām, piemēram, kuņģa vēzim. Pētījumā analizētas Latvijas ģimenes ārstu un gastroenterologu nozīmētās eradikācijas terapijas. Iesaistīti 670 pacienti un kopumā izvērtētas 753 terapijas. Kopējā eradikācijas terapiju efektivitāte sasniedz tikai 73.31% un tā ir zemāka par vadlīnijās noteikto minimālo vēlamo efektivitātes rādītāju (80%). Gastroenterologi biežāk (85.14% gadījumu) kā ģimenes ārsti (70.96% gadījumu) nozīmē efektīvas eradikācijas t…
Multicentric randomised study of
2017
Introduction Population-based eradication of Helicobacter pylori has been suggested to be cost-effective and is recommended by international guidelines. However, the potential adverse effects of widespread antibiotic use that this would entail have not been sufficiently studied. An alternative way to decrease gastric cancer mortality is by non-invasive search for precancerous lesions, in particular gastric atrophy; pepsinogen tests are the best currently available alternative. The primary objective of GISTAR is to determine whether H pylori eradication combined with pepsinogen testing reduces mortality from gastric cancer among 40–64-year-old individuals. The secondary objectives include ev…
Comparative genomics and proteomics of Helicobacter mustelae, an ulcerogenic and carcinogenic gastric pathogen
2010
Abstract Background Helicobacter mustelae causes gastritis, ulcers and gastric cancer in ferrets and other mustelids. H. mustelae remains the only helicobacter other than H. pylori that causes gastric ulceration and cancer in its natural host. To improve understanding of H. mustelae pathogenesis, and the ulcerogenic and carcinogenic potential of helicobacters in general, we sequenced the H. mustelae genome, and identified 425 expressed proteins in the envelope and cytosolic proteome. Results The H. mustelae genome lacks orthologs of major H. pylori virulence factors including CagA, VacA, BabA, SabA and OipA. However, it encodes ten autotransporter surface proteins, seven of which were detec…
Diagnosis of chronic anaemia in gastrointestinal disorders: a guideline by the Italian Association of Hospital Gastroenterologists and Endoscopists (…
2019
Anaemia is a common pathologic condition, present in almost 5% of the adult population. Iron deficiency is the most common cause; other mechanisms can be involved, making anaemia a multi-factorial disorder in most cases. Anaemia being a frequent manifestation in the diseases of the gastrointestinal tract, patients are often referred to gastroenterologists. Furthermore, upper and lower endoscopy and enteroscopy are pivotal to the diagnostic roadmap of anaemia. In spite of its relevance in the daily clinical practice, there is a limited number of gastroenterological guidelines dedicated to the diagnosis of anaemia. For this reason, the Italian Association of Hospital Gastroenterologists and E…
Helicobacter pylori and epstein–barr co-infection in gastric disease
2017
The incidence of gastrointestinal diseases and in particular gastric cancer (GC) is high worldwide. Over the last few years, numerous studies have speculated that Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV) can be correlated with gastric cancerogenesis. Virulence factors of H. pylori can contribute to the variability of clinical outcomes: among the most important virulence factors is the pathogenicity island (CagPAI), vacA and oipA gene. EBV infection usually persists in B cells and induces an inflammatory reaction in cooperation with H. pylori. In Sicily, H. pylori and EBV infections are particularly prevalent, and to our knowledge no study has addressed this yet. The aim …
Role of environmental and genetic factor interaction in age-related disease development: the gastric cancer paradigm.
2008
The association of Helicobacter pylori (Hp) infection with gastric cancer is well known and might be considered a paradigmatic example of the role that interaction among environmental factors and individual background might play in inducing age-associated disease. To evaluate the role of interaction of Hp infection with genetic background, gastric cancer and chronic gastritis patients as well as random selected controls were typed for five inflammation-related polymorphisms of IL-1 and IL-10 cytokine genes. No association among IL-10 or IL-1 variants with an increased risk of gastric cancer was found, whereas an Hp-independent association of IL-1beta -511T positive genotypes to an increased…
Helicobacter pylori: Infection and New Perspective for the Treatment
2019
The alarming phenomenon of antibiotic resistance in Helicobacter pylori suggests to pay close attention in the treatment. In particular, the clarithromycin resistance in H. pylori was designed by the World Health Organization (WHO) as high priority for antibiotic research in 2017 [1]. In Italy, the overall primary resistance to clarithromycin can be detected in 35.2% of cases; in France, it can be detected in 26% of cases, while in Spain, clarithromycin resistance is present in 27.2% of strains [2–4]. Natural/innovative strategies, as well as novel potentiators to restore the antibiotic susceptibility in resistant strains, could be used to improve the efficacy of H. pylori eradication, and …
Helicobacter pylori and Epstein–Barr Virus Co-Infection in Gastric Disease: What Is the Correlation with p53 Mutation, Genes Methylation and Microsat…
2023
Genetic predisposition, environmental factors, and infectious agents interact in the development of gastric diseases. Helicobacter pylori (Hp) and Epstein–Barr virus (EBV) infection has recently been shown to be correlated with these diseases. A cross-sectional study was performed on 100 hospitalized Italian patients with and without gastric diseases. The patients were stratified into four groups. Significant methylation status differences among CDH1, DAPK, COX2, hMLH1 and CDKN2A were observed for coinfected (Hp-EBV group) patients; particularly, a significant presence of COX2 (p = 0.0179) was observed. For microsatellite instability, minor stability was described in the Hp-HBV group (69.23…
A Comparative Study on Nickel Binding to Hpn-like Polypeptides from Two Helicobacter pylori Strains
2021
Combined potentiometric titration and isothermal titration calorimetry (ITC) methods were used to study the interactions of nickel(II) ions with the N-terminal fragments and histidine-rich fragments of Hpn-like protein from two Helicobacter pylori strains (11637 and 26695). The ITC measurements were performed at various temperatures and buffers in order to extract proton-independent reaction enthalpies of nickel binding to each of the studied protein fragments. We bring up the problem of ITC results of nickel binding to the Hpn-like protein being not always compatible with those from potentiometry and MS regarding the stoichiometry and affinity. The roles of the ATCUN motif and multiple His…